Condition: Soft Tissue Sarcoma Adult · Advanced Soft-tissue Sarcoma · Ewing Sarcoma · Sponsor: Institut Bergonié
Phase II trial with three independent strata to independently assess the effects of the association of pembrolizumab and cabozantinib in advanced sarcomas.
This description comes directly from the study's public registry record.
Maud TOULMONDE, MD · +33556333333 · m.toulmonde@bordeaux.unicancer.fr
Simone MATHOULIN-PELISSIER, MD, PhD · s.mathoulin@bordeaux.unicancer.fr
Always discuss trial participation with your own doctor first.
| Institut Bergonie | Bordeaux, France | Recruiting |
| Centre Georges François Leclerc | Dijon, France | Recruiting |
| Centre Oscar Lambret | Lille, France | Not Yet Recruiting |
| Centre Leon Berard | Lyon, France | Not Yet Recruiting |
| Institut Paoli Calmettes | Marseille, France | Recruiting |
| Hôpital La Timone | Marseille, France | Recruiting |
| Institut Curie | Paris, France | Not Yet Recruiting |
| Institut de Cancérologie de l'Ouest - Site René Gauducheau | Saint-Herblain, France | Recruiting |
| IUCT Oncopole | Toulouse, France | Not Yet Recruiting |
| Institut Gustave Roussy | Villejuif, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05182164